Why I View the Blue Chip Retrenchment as a Good Thing

By

companyMany of the stock market’s leading stocks (mostly blue chips) have been pulling back recently, even in the face of rising key stock indices. This is both a telling and healthy development for a market that’s been due for a meaningful retrenchment for a long time.

While a lot of the stock market’s best-performing blue chips aren’t too far off of their highs, there’s definitely been some repositioning going on among institutional investors. This is a possible indicator that the stock market is now rotating out of its safest names that have been performing so well this year. It very much is an equity market dynamic worth following.

One of my favorite stocks for long-term investors seeking dividends is Colgate-Palmolive Company (CL). This is not a burgeoning biotechnology stock, but that’s not the point. If you can get a 10% total return, including dividends, in a year from a company that isn’t going to go broke in the next recession, well, that’s meaningful for a stock market investor who is saving for or is already in retirement.

Colgate-Palmolive is five points off its all-time record high set in May of this year. The stock’s current dividend yield is 2.4%, and its trailing price-to-earnings (P/E) ratio is 24, which many may argue is pricey.

This is a company that has a long-term track record of solid business execution and not surprising Wall Street on the downside. It’s the kind of company worth considering on major retrenchments.

Another favorite of mine for long-term stock market investors is PepsiCo, Inc. (PEP). It’s a better business than The Coca-Cola Company (KO), even if you prefer the taste of “Coke.”

PepsiCo has been a much more consistent company in terms of its share price performance compared to Coca-Cola. It’s also a more consistent earner, and while it’s not the fastest mature enterprise in the landscape, its track record of wealth creation including dividends is undeniable. (See “Two Important Factors Now Working Against Stocks.”) It’s a company that I think will keep on delivering on its promises. Soda and snacks continue to be a very good business.

Finally, one of my favorite benchmarks is still Johnson & Johnson (JNJ). Like many blue chips, this pharma healthcare company has experienced long periods of nonperformance on the stock market. After a sustained period of wealth creation (and this doesn’t account for dividends) in the late 1990s and early 2000s, the company traded range-bound from 2005 until 2012. Then the stock accelerated tremendously to its current level.

Johnson & Johnson is eight points off its record high set in mid-July. It has been one of the stock market’s best wealth creators in the large-cap space, and it remains, in my view, a company worth accumulating when it’s down in price.

I find the price retrenchment among many of the stock market’s leading blue chips to be a meaningful development. Combined with a reduction in quantitative easing, it’s a signal that this stock market is about to experience a change in trend.

Why I View the Blue Chip Retrenchment as a Good Thing

Gold: The Stock Contrarian
Investors' Best Play of the Decade!

Here at Profit Confidential, we believe today's depressed gold prices have created an unprecedented opportunity for contrarian investors to buy struggling gold miners at depressed prices. We first recommended investors get into gold when it traded as low as $300 an ounce back in the early 2000s and we rode the rise in gold prices all the way up to $1,900 an ounce in 2011. We believe the decline in gold prices is a correction in an ongoing bull market in the precious metal. And we've discovered what we believe is the best play for contrarian investors to profit from the coming rebound in gold prices.

"Gold: The Stock Contrarian Investors' Best Play of the Decade!" is yours FREE when you opt-in to get our daily e-letter Profit Confidential. With Profit Confidential you are receiving the opinions and commentaries of seasoned financial analysts and economists. We analyze the actions of the stock market, precious metals, interest rates, real estate, and other investments so we can tell you what we believe today's financial news will mean for you tomorrow!

Combined, we have over 100 years' experience in analyzing various investment markets. Our analysts include MBAs, BAs, B.Comms, P.Engs, MAs, LLBs...and most importantly, years of experience investing and managing our own money successfully!

To opt-in to our FREE e-letter Profit Confidential and to get your FREE report, "Gold: The Stock Contrarian Investors' Best Play of the Decade!," enter your e-mail address in the box below. You can unsubscribe at any time.

We hate spam as much as you do. Check out our Privacy Policy.

About the Author | Browse Mitchell Clark's Articles

Mitchell Clark is a senior editor at Lombardi Financial, specializing in large- and micro-cap stocks. He’s the editor of a variety of popular Lombardi Financial newsletters, including Micro-Cap Reporter, Income for Life, Biotech Breakthrough Stock Report, and 100% Letter. Mitchell has been with Lombardi Financial for 17 years. He won the Jack Madden Prize in economic history and is a long-time student of equity markets. Prior to joining Lombardi, Mitchell was a stockbroker for a large investment bank. In the... Read Full Bio »

Related Articles

Poll

Would you vote for Donald Trump if he was the Republican Nominee?

View Results

Loading ... Loading ...
×
107.21.175.43
From: Michael Lombardi, MBA
Subject: Gold: The Stock Contrarian Investors’ Best Play of the Decade

Read this message